The specialty pharmacy industry is evolving at an extremely rapid pace to manage the influx of new biotech and injectable drug products that is hitting the marketplace. This field is growing more than 20% per year, and some experts predict it will be worth $40 billion by the end of 2006. It’s critical that you understand how these new technologies and therapies will be identified, delivered and paid for.
Specialty Pharmacy: Stakeholders, Strategies and Markets is a valuable one-of-a-kind book full of hard data and statistics on the vendors serving the market, the products involved, and the strategies employed by payers for managing and delivering these products to its members.
The all-new 2007 edition provides readers with unique insight and data on major developments in the market, including:
- Consolidation in the specialty pharmacy and PBM industries, including major acquisitions of home infusion companies
- Distribution strategies, benefit strategies, and sales results for significant new products such as Tysabri, Bexxar, Baraclude, Ventavis, Vivaglobin, Abraxane, Revlimid, Nexavar, Kepivance, Orencia, Saizen, Macugen, Myetta, Thyrogen, Pulminiq, Carticel and Increlex
- Competitive impact of new distribution contracts and new drug launches
- PBM strategies and alliances for competing in the specialty pharmacy space
- Health plan formulary strategies for specific disease states such as oncology, pulmonary arterial hypertension, rheumatoid arthritis, respiratory syncytial virus, infertility, Crohn’s disease/colitis/irritable bowel syndrome, hepatitis, opthalmology, etc.
- Impact of new Average Sales Price (ASP) reimbursement methodologies, Medicare’s Competitive Acquisition Program (CAP) for physician-administered therapies and Part D versus Part B reimbursement controversies
Every health care payer, provider or supplier operating today will be affected by market changes brought about by new biotech products, gene-based therapies and injectable drugs. And each stakeholder has unique capabilities and strengths to contribute to the development of the specialty pharmacy marketplace. Specialty Pharmacy: Stakeholders, Strategies and Markets provides concrete tips and strategies for exploiting opportunities in this evolving field.
Also Available on CD: For an additional $150, you can order the convenient CD edition of Specialty Pharmacy: Stakeholders, Strategies and Markets along with the printed book. The CD contains all of the information in the print edition and you’ll find what you need instantly with the user-friendly, searchable PDF format.
Table of Contents
Chapter 1: Growth of the Specialty Pharmacy Market
- Expanding Definitions and Core Competencies in Specialty Pharmacy
- Market Size Estimates and Projections
- Market Forces Driving Specialty Pharmacy
- Financial Performance of Specialty Pharmacy Companies
Chapter 2: Specialty Pharmacy Markets by Therapeutic Category
Chapter 3: Payer Contracting and Reimbursement Issues
- Decisions in Building a Specialty Pharmacy Program
- Provider Contracting Issues
- Strategies of Specific Managed Care Organizations
Chapter 4: Benefit Structure, Formularies and Emerging Management Strategies
- Medical Benefit vs. Pharmacy Benefit vs. Integrated Benefit Design
- Trends in Therapy Management
- Member Cost-Sharing Strategies
- Formulary Placement and Product Preferencing
- Biosimilar Opportunities
- Drug Safety
- Other Management Issues
Chapter 5: Payer Strategies for Managing Specific Disease States
- Oncology
- Pulmonary Arterial Hypertension (PAH)
- Rheumatoid Arthritis
- Respiratory Syncytial Virus (RSV)
- Fertility
- Crohn’s Disease/Colitis/Irritable Bowel Syndrome
- Hepatitis
- Ophthalmology
Chapter 6: Specialty Pharmacy Business Models and Stakeholder Perspectives
- Class of Trade Issues
- Payer-Centric Business Models
- Mergers & Acquisitions Focus on Capabilities Expansion
- Home Infusion, Specialty Infusion Drive New Business Models
- Group Purchasing Organizations
- Disease Management
- Legal Challenges and Considerations
Chapter 7: Impact of Medicare Programs and Strategies for Injectables Management
- Medicare Part B Physician Fee Schedule
- Average Sales Price (ASP)-Based Reimbursement for
- Medicare Part B Drugs and Biologicals
- Competitive Acquisition Program (CAP) for Physician-Administered Drugs
- Part D vs. Part B Reimbursement Controversies
Chapter 8: Pharmaceutical Distribution Strategies
- Manufacturer Distribution Strategies
- New Drug Launches and Payer Reaction
- FDA Approvals and Expanded Indications
Chapter 9: Specialty Pharmacy Vendor Shopping Guide
- Vendor Comparison Analysis
- Business Volume Indicators
- Comprehensive Directory of Specialty Pharmacy Vendors
Written For
- Managed care payers
- Disease management companies
- Pharmaceutical retailers
- Physicians
- Pharmaceutical and biotech developers and manufacturers
- Pharmacy benefit managers
- Pharmaceutical distributors
- Home health providers
- Specialty outpatient clinics
International orders will be fulfilled in PDF format via email.
